Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (5 to 100 mg q.d. for 14 Days) of BI 135585 XX in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups).
Phase of Trial: Phase I
Latest Information Update: 01 May 2016
At a glance
- Drugs BI 135585 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 23 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 27 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.